DK2240017T3 - KETONLEGES AND CETONLE CUSTOMERS AS A BLOOD LIPID-DEVICE - Google Patents

KETONLEGES AND CETONLE CUSTOMERS AS A BLOOD LIPID-DEVICE Download PDF

Info

Publication number
DK2240017T3
DK2240017T3 DK09701051.6T DK09701051T DK2240017T3 DK 2240017 T3 DK2240017 T3 DK 2240017T3 DK 09701051 T DK09701051 T DK 09701051T DK 2240017 T3 DK2240017 T3 DK 2240017T3
Authority
DK
Denmark
Prior art keywords
ketonleges
cetonle
customers
blood lipid
lipid
Prior art date
Application number
DK09701051.6T
Other languages
Danish (da)
Inventor
Richard Lewis Veech
Kieran Clarke
Original Assignee
Univ Oxford Innovation Ltd
The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services filed Critical Univ Oxford Innovation Ltd
Application granted granted Critical
Publication of DK2240017T3 publication Critical patent/DK2240017T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK09701051.6T 2008-01-04 2009-01-05 KETONLEGES AND CETONLE CUSTOMERS AS A BLOOD LIPID-DEVICE DK2240017T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1896208P 2008-01-04 2008-01-04
PCT/US2009/030095 WO2009089144A1 (en) 2008-01-04 2009-01-05 Ketone bodies and ketone body esters as blood lipid lowering agents

Publications (1)

Publication Number Publication Date
DK2240017T3 true DK2240017T3 (en) 2019-06-17

Family

ID=40853425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09701051.6T DK2240017T3 (en) 2008-01-04 2009-01-05 KETONLEGES AND CETONLE CUSTOMERS AS A BLOOD LIPID-DEVICE

Country Status (8)

Country Link
US (4) US9211275B2 (en)
EP (1) EP2240017B1 (en)
CN (2) CN106038532B (en)
AU (1) AU2009204370B2 (en)
DK (1) DK2240017T3 (en)
ES (1) ES2730879T3 (en)
TR (1) TR201908522T4 (en)
WO (1) WO2009089144A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
CN106038532B (en) 2008-01-04 2019-05-14 牛津大学科技创新有限公司 As the ketoboidies and ketoboidies ester for reducing blood lipid medicament
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EP3659595A1 (en) * 2012-11-05 2020-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
WO2014140308A1 (en) 2013-03-14 2014-09-18 Isis Innovation Ltd Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
KR102499654B1 (en) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 Compositions and methods for producing elevated and sustained ketosis
CN106461636A (en) * 2014-01-10 2017-02-22 重症监护诊断股份有限公司 Methods and systems for determining risk of heart failure
JP6721583B2 (en) 2014-07-21 2020-07-15 オウルン イリオピストＯｕｌｕｎ Ｙｌｉｏｐｉｓｔｏ Oligomer of 3-hydroxybutyrate
CN104940181B (en) * 2015-06-29 2018-02-16 齐锦生 The purposes of β hydroxybutyric acids or its pharmaceutically acceptable salt
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
GB201616058D0 (en) 2016-09-21 2016-11-02 Chain Biotechnology Ltd Probiotic composition
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
CA3053663C (en) * 2017-04-12 2021-09-07 Franco CAVALERI Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
CN107083406B (en) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 Method for producing (R) -3-hydroxybutyric acid
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
JP6571298B2 (en) * 2017-08-18 2019-09-04 拓己 佐藤 Glycemic spike inhibitor, food, and method for producing blood glucose spike inhibitor
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
EP3801496A4 (en) * 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
CN113660930A (en) * 2019-02-11 2021-11-16 阿克塞斯全球科学有限责任公司 Beta-hydroxybutyrate mixed salt-acid compositions and methods of use
AU2020222897A1 (en) * 2019-02-11 2021-09-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
CN109806251A (en) * 2019-03-04 2019-05-28 清华大学 The application of 3-hydroxybutyrate and its derivative in the product for preparing antiatherosclerosis
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN110776425B (en) * 2019-10-23 2021-02-26 清华大学 Preparation method of (R) -3-hydroxybutyric acid and oligomer thereof
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
CN117677383A (en) * 2021-07-17 2024-03-08 瑞士凯托股份公司 Combinations of ketone bodies or ketone-forming compounds, analgesics or antioxidants
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU507322A1 (en) 1973-07-26 1976-03-25 Московский Научно-Исследовательский Институт Косметологии Regulator of hormonal exchange of skin
US3984566A (en) 1974-02-25 1976-10-05 Scott Eugene J Van Method of alleviating the symptoms of dandruff
IT1051853B (en) 1975-01-07 1981-05-20 Basf Ag BUTANDIOL 1.3 3 MONO 3 IDROS SIBUTIRRATI BUTANDIOL 1.3 1MONO 3 HYDROXYBUTIRRATES AND PROCESSES FOR THEIR PREPARATION
US4380549A (en) 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
JPS54138126A (en) 1978-04-17 1979-10-26 Ajinomoto Co Inc Remedy for diabetes
WO1987003806A1 (en) 1985-12-18 1987-07-02 Veech Richard L Parenteral nutrition therapy with amino acids
JPH0755158B2 (en) 1986-10-30 1995-06-14 チッソ株式会社 Method for producing optically active ester
JP2579779B2 (en) 1987-10-08 1997-02-12 日本車輌製造株式会社 Feed production
BE1001209A3 (en) 1987-11-19 1989-08-22 Solvay PHARMACEUTICAL CONTAINING ACID DERIVATIVE 3-hydroxybutanoic CHOSEN AMONG OLIGOMERS OF THIS ACID AND ESTERS OF THIS ACID OR WITH THESE OLIGOMERS 1.3-BUTANEDIOL.
JPH0383950A (en) 1989-08-28 1991-04-09 Kanegafuchi Chem Ind Co Ltd Glyceride derivative and its production
JP2873497B2 (en) 1990-09-03 1999-03-24 理化学研究所 Lipid metabolism regulator
JP2884123B2 (en) 1992-01-17 1999-04-19 高砂香料工業株式会社 Biodegradable optically active polymer, intermediate oligomer thereof, and production method thereof
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US5281691A (en) 1992-06-19 1994-01-25 Eastman Kodak Company Poly(3-hydroxyalkanoates)
JP3193542B2 (en) 1993-09-08 2001-07-30 カネボウ株式会社 Anti-aging skin cosmetics
WO1995009144A1 (en) 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
DE59508729D1 (en) 1994-08-10 2000-10-26 Peter Neuenschwander Biocompatible block copolymer
US6306828B1 (en) 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JP4598203B2 (en) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド Brain function improver
US6126953A (en) 1996-08-19 2000-10-03 The Procter & Gamble Company Fragrance delivery systems for personal care articles
JPH10175855A (en) 1996-10-16 1998-06-30 Taisho Pharmaceut Co Ltd Physical fatigue relieving agent
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
JPH10265378A (en) 1997-03-25 1998-10-06 Ofutekusu:Kk Therapeutic agent for ectocornea injury
WO1998051302A1 (en) 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US6727258B2 (en) 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
ES2234276T3 (en) 1998-07-22 2005-06-16 Metabolix, Inc. NUTRITIONAL AND THERAPEUTIC UTILIZATIONS OF 3-HYDROXIALCANOATE OLIGOMERS.
EP1123094B1 (en) * 1998-09-15 2007-04-11 Btg International Limited Therapeutic compositions (ii)
AU6988100A (en) 1999-08-20 2001-03-19 Unilever Plc A method for reducing skin irritation and sting from weak carboxylic acid
EP1248849B1 (en) 2000-01-14 2008-08-20 Serono Genetics Institute S.A. Obg3 globular head and uses thereof for decreasing body mass
DE60138019D1 (en) 2000-05-01 2009-04-30 Accera Inc USE OF TRIGLYCERIDES WITH MEDIUM-WIDE CHAINS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE
WO2002006368A2 (en) 2000-07-14 2002-01-24 Metabolix, Inc. Polyurethanes obtained from hydroxyalkanoates and isocyanates
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
DE20205184U1 (en) 2002-03-27 2002-12-19 Bartz Volker Blood lipid lowerers for oral use
CN1483355A (en) 2002-09-16 2004-03-24 岚 高 Anti-fatigue beverage formula
ES2574918T3 (en) 2003-06-02 2016-06-23 Isis Innovation Limited Muscle fatigue treatment
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
JP2005247821A (en) * 2004-02-06 2005-09-15 Ophtecs Corp Ophthalmic composition for suppressing production of inflammatory cytokine
DE102004007029A1 (en) 2004-02-12 2005-09-08 Consortium für elektrochemische Industrie GmbH Process for the enantioselective reduction of keto compounds by enzymes
WO2006020137A2 (en) 2004-07-16 2006-02-23 Ketocytonyx Inc. Oligomeric compounds
EP1778615A4 (en) * 2004-07-20 2010-01-06 Btg Int Ltd Oligomeric ketone compounds
EP1778212A4 (en) * 2004-07-23 2010-12-08 Btg Int Ltd Ketogenic saccharides
US8124063B2 (en) 2004-10-25 2012-02-28 Conopco, Inc. Method for moisturizing human skin using dihydroxypropyltri(C1-C3 alkyl) ammonium salts
ITTO20040918A1 (en) 2004-12-29 2005-03-29 Luigi Ambrosio POLYMERIC HYDROGEL BIODEGRADABLE ABSORBERS AND PROCEDURE FOR THEIR PREPARATION
WO2007001883A2 (en) 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US8273555B2 (en) 2005-11-29 2012-09-25 Basf Aktiengesellschaft Process for esterifying or transesterifying side chains in polymers
EP2001293B9 (en) 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
EP2004160B1 (en) 2006-04-12 2012-09-19 Unilever PLC Oral composition with an antiageing effect on the skin
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
JP5030553B2 (en) 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 Pharmaceuticals for treating dry mice and / or salivary secretion disorders
WO2008119032A1 (en) 2007-03-27 2008-10-02 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
EP2150265A4 (en) 2007-05-14 2010-06-09 Neuera Pharmaceuticals Inc Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
WO2009023357A2 (en) 2007-05-25 2009-02-19 University Of Rochester Curcumin derivatives and their use as radioprotectors
CN106038532B (en) 2008-01-04 2019-05-14 牛津大学科技创新有限公司 As the ketoboidies and ketoboidies ester for reducing blood lipid medicament
ES2907630T3 (en) 2008-08-21 2022-04-25 The Government Of The United States Of America As Repres By The Secretary Of Health And Human Servic Non-therapeutic use of hydroxybutyrate ester
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
AU2009344282B2 (en) 2009-04-16 2014-12-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
FR2958154B1 (en) 2010-04-01 2012-06-08 Oreal PROCESS FOR CARING AND / OR MAKE-UP WRINKLES
US20120213835A1 (en) 2011-02-17 2012-08-23 Chd Bioscience, Inc. Compositions Comprising Peroxy alpha-Ketocarboxylic Acid and Methods For Producing and Using the Same
WO2012113415A1 (en) 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
EP3659595A1 (en) 2012-11-05 2020-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
WO2014140308A1 (en) 2013-03-14 2014-09-18 Isis Innovation Ltd Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown

Also Published As

Publication number Publication date
CN101969769A (en) 2011-02-09
CN106038532A (en) 2016-10-26
US11311509B2 (en) 2022-04-26
US20160193173A1 (en) 2016-07-07
ES2730879T3 (en) 2019-11-13
EP2240017A4 (en) 2011-02-16
US20190201366A1 (en) 2019-07-04
WO2009089144A1 (en) 2009-07-16
US10154982B2 (en) 2018-12-18
US9211275B2 (en) 2015-12-15
CN106038532B (en) 2019-05-14
AU2009204370B2 (en) 2014-12-04
US20230075547A1 (en) 2023-03-09
TR201908522T4 (en) 2019-07-22
EP2240017A1 (en) 2010-10-20
EP2240017B1 (en) 2019-03-13
US20100298294A1 (en) 2010-11-25
AU2009204370A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
DK2240017T3 (en) KETONLEGES AND CETONLE CUSTOMERS AS A BLOOD LIPID-DEVICE
DK1987765T3 (en) Oximeter
DK2240487T3 (en) Triazolopyridazines as para-inhibitors, their preparation and use as a drug
FR2937843B1 (en) MEDICAL PARAVENT
TH97348B (en) bracelet
UA18696S (en) BRACELET
UY3831Q (en) BRACELET
TH97352B (en) bracelet
TH97351B (en) bracelet
TH97350B (en) bracelet
TH97349B (en) bracelet
TH97346B (en) bracelet
TH97347B (en) bracelet
UA18325S (en) SOFA
ITPR20080001A1 (en) SOFA
UA18872S (en) SOFA
UA18947S (en) SOFA
UA17979S (en) SOFA
UA18871S (en) SOFA
UA18946S (en) SOFA
UA14693S (en) SOFA
TH94239B (en) sofa
UA17242S (en) SOFA
UA17149S (en) SOFA
UA17007S (en) SOFA